ArticleNeurology and therapy2026

Atogepant for the Preventive Treatment of Migraine in Japanese Participants: A Phase 3, Open-Label, 52-Week Extension Study.

Yasuhiko Matsumori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.